Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1992-06-25
1994-03-08
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 12, 530381, A61K 3702, A61K 4736
Patent
active
052927245
ABSTRACT:
An intraocular anticoagulant including antithrombin III is applicable as an injection into the ocular chamber of the eye at the time of cataract surgery, intraocular lens implant surgery, and other ocular surgeries. The anticoagulant prevents fibrin deposits from forming on the intraocular lens surface after surgery and avoids postoperative viscoelastic material inducing transient elevation in intraocular pressure.
REFERENCES:
patent: 4141973 (1979-02-01), Balazs
patent: 4340589 (1982-07-01), Uemura et al.
patent: 4731080 (1988-03-01), Galin
patent: 5182259 (1993-01-01), Kita
Robert D. LeBoeuf et al., Human Fibrinogen Specifically Binds Hyaluronic Acid, The Journal of Biological Chemistry, vol. 261, No. 27, pp. 12586-12592, 1986.
Bruce A. Barron et al., Comparison of the Effects of Viscoat and Healon on Postoperative Intraocular Pressure, American Journal of Ophthalmology 100:377-384, Sep. 1985.
Yoshitomi et al., Postoperative Fluctuations of Tissue Plasminogen Activator (t-PA) in Aqueous Humor of Pseudophakes, pp. 1-9 w/ Figs.
Proceedings of the Advanced Viscosurgery Techniques Symposium (1986), pp. 1-23.
Letters to the Editor of: Ocular Surgery News, Chicago, Ill. Jun. 15, 1990, p. 3.
Joe Ho Kim, M.D., Intraocular Inflammation of Denatured Viscoelastic Substance in Cases of Cataract Extraction and Lens Implantation, vol. 13, Sep. 1987, pp. 537-542, Journal of Cataract Refract, Surg.
Phillip C. Hoopes, Sodiumhyaluronate (Healon.RTM.) in Anterior Segment Surgery: A Review and a New Use in Extracapsular Surgery, vol. 8, Spring 1982, pp. 184-159. AM Intra-Ocular Implant Society Journal.
Elizabeth D. Sharpe, M.D., A Prospective Comparison of Amvisc.RTM. and Healono in Cataract Surgery, vol. 12, Jan. 1986, pp. 47-49.
Howard L. Bleich et al., Actions and Interactions of Antithrombin and Heparin, New England Journal of Medicine, Jan. 16, 1975 pp. 146-151.
Ewa Marciniak et al., Catabolism and Distribution of Functionally Heterogeneous Human Antithrombin III, J. Lab. Clin. Med., Jan. 1987, pp. 89-96.
Eberhard F. Mammen et al., The Role of Antithrombin III in Dic, Biologia & Clinic Hematologica, 9, Supl. 1, 69-73, 1987.
Endre A. Balazs, chapter on Sodium Hyaluronate and Viscosurgery, Healon, pp. 5-28.
Heparin, Lane and Lindhal, i Edward Arnold 1989, Great Britain, pp. Index 2-3, 18, 73-75, 164-165, 176, 180-181, 229-255, 260-262, 276-277, 288-291, 363-364, 366, 368, 388, 423, 438-439, 501, 562, 563-564, 577-578, 597-601.
Marciniak et al., Heparin-Induced Decrease in Circulating Antithrombin-III, Lancet, Sep. 17, 1977, pp. 581-584.
Ocular Surgery News, cover, p. 40, vol. 9, No. 18, Sep. 15, 1991.
Arch Ophthalmol, p. 1666, vol 108, Dec. 1990.
Antithrombin, Pamphlet, Kabi Plasma Product Sweden, Jun. 1989.
Antithrombin III Kabi, Pamphlet, pp. 57 & 58, KabiVitrum, Sweden, Jun. 1989.
Fragmin, Pamphlet, pp. 18, 19 & 40, Kabi, Sweden 1988.
Statement of Virtues, Healon, Pharmacia Ophthalmic, Inc. USA.
Poster Symposium XVIII, Thrombosis: Structure and Activities of Antithrombin III, Thromb. Haemostas. 38:201A (1977), pp. 201-203.
Koh Choon
Wityshyn Michael G.
LandOfFree
Intraocular anticoagulant including antithrombin III and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intraocular anticoagulant including antithrombin III and method , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intraocular anticoagulant including antithrombin III and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-153295